![Jason Keyes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jason Keyes
Financieel Directeur/CFO bij
BLOSSOMHILL THERAPEUTICS, INC.
Vermogen: 405 226 $ op 30-06-2026
Profiel
Jason A. Keyes is currently an Independent Director at Actuate Therapeutics, Inc. since 2024 and Chief Financial Officer & Executive Vice President at Blossomhill Therapeutics, Inc. starting in 2025.
Former roles include Chief Financial Officer at Equillium, Inc. from 2018 to 2025, Independent Director at Sesen Bio, Inc. from 2020 to 2023, Chief Financial Officer & Executive Vice President at Orexigen Therapeutics, Inc. from 2016 to 2018, Senior Director-Finance at Amylin Pharmaceuticals, Inc. from 2007 to 2013, and Head-Finance & Strategy at Amgen, Inc. Education includes undergraduate and graduate degrees from Stanford University and an MBA from UCLA Anderson School of Management.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
EQUILLIUM, INC. 0,2% | 14-02-2025 | 126.633 ( 0,2% ) | 405 226 $ | 30-06-2026 |
| 21-05-2026 | 0 ( -.--% ) | - $ | 30-06-2026 | |
| 06-08-2026 | 0 ( -.--% ) | - $ | 30-06-2026 |
Actieve functies van Jason Keyes
| Bedrijven | Functie | Begin |
|---|---|---|
| ACTUATE THERAPEUTICS, INC. | Directeur/Bestuurslid | 12-08-2024 |
| BLOSSOMHILL THERAPEUTICS, INC. | Financieel Directeur/CFO | 01-05-2025 |
Eerdere bekende functies van Jason Keyes
| Bedrijven | Functie | Einde |
|---|---|---|
| EQUILLIUM, INC. | Financieel Directeur/CFO | 25-04-2025 |
| CARISMA THERAPEUTICS, INC. | Directeur/Bestuurslid | 07-03-2023 |
| OREXIGEN THERAPEUTICS, INC. | Financieel Directeur/CFO | 23-02-2018 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Financieel Directeur/CFO | 01-01-2013 |
| AMGEN INC. | Corporate Officer/Principal | - |
Opleiding van Jason Keyes
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
58
Eerstegraads connecties
9
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 9 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on the treatment of obesity | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops protein therapeutics to treat eye diseases | Health Technology |
UCLA Anderson School of Management
 UCLA Anderson School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Actuate Therapeutics, Inc.
 Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops novel therapeutics which target cancers and neurodegenerative diseases | Health Technology |
Equillium, Inc.
 Equillium, Inc. BiotechnologyHealth Technology Engages in the development of products for severe immune-inflammatory disorders | Health Technology |
Blossomhill Therapeutics, Inc.
 Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for oncology and autoimmune diseases | Health Technology |
